March 24, 2020 / 12:28 PM / 14 days ago

BRIEF-Aravive Announces Initiation Of Investigator-Sponsored Phase 1/2 Study Of AVB-500 In Combination With Avelumab

March 24 (Reuters) - Aravive Inc:

* ARAVIVE ANNOUNCES INITIATION OF INVESTIGATOR-SPONSORED PHASE 1/2 STUDY OF AVB-500 IN COMBINATION WITH AVELUMAB IN PATIENTS WITH ADVANCED UROTHELIAL CARCINOMA (COAXIN)

* ARAVIVE INC - PATIENT ENROLLMENT AND CONTINUATION ON STUDY MAY BE IMPACTED BY COVID-19 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below